Etop Ibcsg Partners Foundation

This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researcher…

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well the drugs slow tumor growth before s…

This study looked at two different hormone therapy combinations for premenopausal women with a type of breast cancer that grows in response to hormones. Over 2,600 women who had surgery to remove their cancer were randomly assigned to receive either exemestane plus triptorelin or…

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…

This study looked at whether shutting down the ovaries (ovarian suppression) combined with hormone therapy (tamoxifen or exemestane) could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery t…